Key Highlights

  • Scinai Immunotherapeutics (NASDAQ:SCNI) closed at USD 1.18 in the October 9, 2026 session, down 2.48%, and sits only a few cents above its published 52-week low of USD 1.12.
  • Published market data shows trading volume of 89,304 shares against a three-month average of 1.1M, so activity was roughly 8% of normal, simple arithmetic on two published numbers.
  • The published market capitalization is USD 1.637M, which is unusually small for a listed company and should be rechecked before anyone relies on the figure.
  • No company-specific catalyst was identified for the session, so the move reflects published market data and the pressure that usually affects very small biotech shares.

Where the Price Sits in Its Yearly Range

Scinai Immunotherapeutics (NASDAQ:SCNI) ended the October 9, 2026 session at USD 1.18, a decline of USD 0.03 or 2.48%. The published 52-week range runs from USD 1.12 to USD 15.80, which places the closing price about 5% above the low and far below the high. A fall of that scale over twelve months means holders have seen most of their value disappear. The company is an Israeli biopharma, formerly known as BiondVax, that develops inhaled nanobody medicines based on VHH antibodies and also offers contract development and manufacturing services. Companies at this stage of development rarely generate meaningful revenue, so the share price depends heavily on financing news and clinical progress.

What a Sub-USD 2 Biotech Faces

Very small biotech companies must keep paying for laboratories, staff and trials while earning little revenue, so cash runway is the central question. When cash runs low, management often raises money by selling new shares, which dilutes existing holders and can push the price lower. Nasdaq also requires listed shares to hold a minimum bid of USD 1.00, and a company that closes below that level for an extended period can receive a deficiency notice and may later need a reverse stock split to regain compliance. Scinai Immunotherapeutics (NASDAQ:SCNI) is trading only modestly above that threshold, so these mechanics are relevant background, although no notice has been identified in the information reviewed.

How High Short Interest Fits In

Scinai Immunotherapeutics (NASDAQ:SCNI) appears among names with high short interest positions, meaning a meaningful number of traders have sold borrowed shares in the expectation of lower prices. A short squeeze happens when the price rises and short sellers buy shares to close positions, which adds to the rise. That needs buying demand, and the October 9, 2026 session showed the opposite: volume was light and the price slipped. High short interest is therefore a description of positioning and not a prediction. Broader conditions also matter, with the Fed policy rate at 3.75% to 4.00% after the September hike and the 10-year Treasury yield near 5.25% making funding harder for cash-burning companies.

Where Things Stand

The answer to why Scinai Immunotherapeutics (NASDAQ:SCNI) is near its 52-week low is that no company-specific catalyst was identified for the October 9, 2026 session. The shares closed at USD 1.18 after a 2.48% decline, with light volume of 89,304 shares and a published market capitalization of USD 1.637M that needs checking. The pattern fits a cash-consuming biotech where dilution risk and the Nasdaq USD 1.00 minimum bid rule weigh on sentiment. The S&P 500 closed at 7,811.5, just below its record, so the weakness is specific to the stock. The next markers are the CPI report on October 14 and bank earnings from October 13.